Table VII.
Study reports for specific positive experiences (No.=4) and specific negative experiences (No.=91)
| Specific experience | Study reports of experiences | Range % participants reporting experiences in studies | Mean % participants reporting experiences in studies | Median % participants reporting experiences in studies | No. (%) Continent study reports occurred | ||
|---|---|---|---|---|---|---|---|
| Label | Qual No. | Quant No. | Total No. (%) | ||||
| Positive experiences | |||||||
| Vitality | - | 1 | 1 (25.0) | 11.9 | 11.9 | - | 1 (100.0) Europe |
| Improving blood | 3 | - | 3 (75.0) | - | - | - | 1 (33.0) Asia 2 (67.0) South America |
| Negative experiences | |||||||
| Immunity | 1 | 2 | 3 (3.3) | 0.8–2.9 | 1.9 | 1.9% | 1 (33.0) Africa 2 (67.0) Asia |
| Vitality | 0 | 16 | 16 (17.6) | 0.9–52.6 | 12.2% | 7.7% | 1 (6.3) Africa 6 (37.5) Asia 4 (25.0) Europe 3 (18.8) North America 2 (12.5) Oceania |
| Iron | 1 | 1 | 2 (2.2) | 56.0 | 56.0 | 56.0 | 2 (100.0) Asia |
| Infectious disease | 0 | 1 | 1 (1.0) | 1.1 | 1.1 | 1.1 | 1 (100.0) Europe |
| Headaches | 0 | 2 | 2 (2.2) | 0.4–1.0 | 0.7 | 0.7 | 2 (100.0) Europe |
| Adverse events: non-specific | 0 | 21 | 21 (23.1) | 0.1–51.8 | 18.8 | 13.0 | 7 (33.3) Asia 5 (23.8) Europe 6 (28.6) North America 3 (14.3) Oceania |
| Adverse events: vasovagal reactions | 2 | 27 | 29 (31.9) | 0.0–32.1 | 9.6 | 7.2 | 1 (3.4) Africa 9 (31.0) Asia 9 (31.0) Europe 7 (24.1) North America 3 (10.3) Oceania |
| Adverse events: other physical | 1 | 16 | 17 (18.7) | 0.0–70.5 | 13.2 | 4.8 | 9 (52.9) Asia 2 (11.8) Europe 5 (29.4) North America 1 (5.9) Oceania |